, /PRNewswire/ -- Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in through internal development, licensing and acquisitions. In , MTPC first received approval for Argatroban in in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including , the UK, , and . Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications.
Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II. , CEO of Ethypharm, said: " " Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine. Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.
Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations. The six production sites located in , the UK, , and have expertise in injectables and complex oral solid forms. With a global pres.
